The US Supreme Court has refused to look at the result of a federal lawsuit between GSK and Teva over so-called ‘skinny labels’ for generic drugs, despite a request from t
Shares in Biogen have come under pressure after chief executive Michel Vounatsos admitted that the company is facing a much slower than anticipated rollout of its controversial Alzheimer's